Oncotherapy Solutions, LLC
  
                         

Home

Focusing on scientific discovery and innovation in targeted therapy and immuno-oncology to save human lives: 

Cancer is the second most common cause of death in the US, exceeded only by heart disease.
 One of every four deaths in the United States is due to cancer.  The American Cancer Society estimates that in 2014, about 1,665,540 Americans were diagnosed with invasive cancer, and 585,720 Americans died of this disease.  Currently used cancer drugs such as chemotherapeutic agents and monoclonal antibodies have limitations due to their toxicities and are ineffective against tumors with drug resistance.  Thus, there is an urgent need for more potent, targeted and safer cancer therapeutics.  Oncotherapy Solutions, a new biotechnology company is utilizing its previous expertise in preclinical drug development and delivery to design and test new pipeline of targeted, potent, stable and safer drug conjugates, kinase inhibitors and vaccines for the treatment of prostate, ovarian, breast, colon, pancreatic and lung cancers. 


The company currently has two preclinical programs:


The first program is focused on the development of novel, potent and safer drug conjugates carrying new chemotherapeutic agents.  
Our new lead drug conjugate showed a dramatic tumor growth inhibition of multiple triple-negative breast cancer models.  A single intravenous injection of 1.5 mg/kg animal weight of the new lead drug conjugate caused a 100% tumor growth inhibition of HCC1806 TNBC model with the majority of mice showing complete response.  Toxicology studies showed no effect on animal weight, white blood cells or normal organs suggesting the safety of our new drug conjugate.  Using humanized female NSG-SGM3 mice bearing BR1126 patient-derived tumors we have also shown that combination of our initial drug conjugate at a suboptimal dosing regimen with anti-PD1 antibody Pembrolizumab is superior to either monotherapy.  We are looking forward to perform additional immuno-oncology studies on our new drug conjugate especially the effect on intratumoral immunosuppressive cells namely T regulatory cells (Tregs), M2 macrophages and myeloid derived suppressor cells (MDSCs) as well as on cytotoxic CD8 T cells and natural killer cells.  We will further perform safety pharmacology of our lead drug conjugate in cynomolgus monkey with the goal to submit IND application to the FDA and start clinical trials upon availability of additional funds.
 
The second program is focused on the development of new immunotherapy small molecule
 drugs that will help patient's own immune system, namely cytotoxic T cells and natural killer cells to seek and destroy cancer cells. Our future plan is to screen well-designed small molecule drugs for the treatment of TNBC and CRPC as well as drug-resistant ovarian, pancreatic and colon cancers. 
Website Builder